

A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer

NCT07450976

Status	RECRUITING
Phase	Phase 2
Sponsor	Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Enrollment	151 participants

Key Eligibility Criteria

Inclusion (9)

- Age 18-75 years old (including both ends), male or female;
- ECOG-PS score: 0 or 1;
- Expected survival e 12 weeks;
- Locally advanced or metastatic biliary tract cancer confirmed by histopathology or cytology;
- CLDN18.2 positive expression;

... and 4 more (see full listing online)

Exclusion (12)

- Received anti-tumor treatment such as chemotherapy, radiotherapy, immunotherapy, biotherapy or other clinical research drugs within 4 weeks before the first administration;
- Other active malignancies within 5 years or at the same time;
- Subjects with a history or evidence of brain metastasis or meningeal metastasis;
- With acute or chronic uncontrolled pancreatitis or Child-Pugh liver function grade C;
- Severe trauma or major surgery was performed within 4 weeks before the first administration;

... and 7 more (see full listing online)

Locations (2 total)

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China
Zhongshan Hospital, Fudan University, Shanghai, Shanghai Municipality, China